Emerging retatrutide, a combined-action medication targeting simultaneously GLP-1 and GIP receptors, is sparking considerable buzz within the medical community. Initial clinical trials have shown significant decreases in physical mass and improvements in physiological markers for patients with excess weight . Scientists believe this ground-breaking